Recce Pharmaceuticals’ Expert KOL Webinar: How R327 is leading the way as a potential, robust solution to Sepsis and Superbugs
|DATE:||June 21, 2022|
|TIME:||8:00 AM EDT|
About The Event
The event will feature a presentation from Key Opinion Leader Thomas Heymann (President & CEO of Sepsis Alliance, USA), who will discuss the current treatment landscape and unmet medical need in treating patients with sepsis.
Sepsis patient advocate Mary Millard (International Speaker, Hospital Infections & Prevention) will speak about her journey, the unmet need, and the current standard of care in place. The Recce leadership team will discuss RECCE® 327 intravenous formulation as a potential novel treatment solution.
A live question and answer session will follow.